Athira Pharma Inc Ordinary Shares ATHA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Athena Gold Samples Up To 50.6 g/t Gold from Buster Mine at Excelsior Springs Project, Walker Lane, Nevada
-
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
-
Athena Gold Announces Transformative Transaction With Libra To Create a Premier, Discovery Focused Gold Explorer in Nevada and Ontario, With Enhanced Board and Management Team and Plans to Redomicile to Canada
-
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
-
Athena Gold Corporation Completes Acquisition of the Historic Blue Dick Mine and Significantly Expands Its Flagship Excelsior Springs Gold Project in Nevada
-
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
-
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
-
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 67
- Website
- https://www.athira.com
Comparables
Valuation
|
Metric
|
ATHA
|
TVTX
|
TSHA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 53.09 |
Price/Book Value | 0.20 | 70.72 | 3.83 |
Price/Sales | — | 6.06 | 32.20 |
Price/Cash Flow | — | — | — |
Price/Earnings
ATHA
TVTX
TSHA
Financial Strength
|
Metric
|
ATHA
|
TVTX
|
TSHA
|
|---|---|---|---|
Quick Ratio | 3.47 | 2.89 | 5.05 |
Current Ratio | 3.97 | 3.04 | 5.22 |
Interest Coverage | — | −35.20 | −52.79 |
Quick Ratio
ATHA
TVTX
TSHA
Profitability
|
Metric
|
ATHA
|
TVTX
|
TSHA
|
|---|---|---|---|
Return on Assets (Normalized) | −65.48% | −9.03% | −40.83% |
Return on Equity (Normalized) | −79.15% | −47.00% | −216.63% |
Return on Invested Capital (Normalized) | −78.21% | −13.68% | −77.31% |
Return on Assets
ATHA
TVTX
TSHA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qwpctqxkt | Slfh | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ffcylhzph | Trgbvnt | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ycvdvtvcw | Jwysfb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wpbgpgwx | Wqhkxh | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Vhqhxpcs | Yrw | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fvsylzqmk | Qclc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Hpqkbbk | Jnfq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nyydgvpt | Wrqk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rxqjflpt | Zshpxrp | $13.4 Bil | |||
| Incyte Corp
INCY
| Vkltyrb | Qmwdmgs | $12.7 Bil |
United States